Allogeneic adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Drug Profile

Allogeneic adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Alternative Names: AlloJoin; haMPC - Cellular Biomedicine Group

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Cellular Biomedicine Group
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 09 Dec 2016 Interim adverse events data from a phase I trial in Osteoarthritis released by Cellular Biomedicine
  • 09 Aug 2016 Interim safety data from a phase I trial in Osteoarthritis released by Cellular Biomedicine
  • 14 Mar 2016 Cellular Biomedicine Group plans a registrational trial for Osteoarthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top